SCHEMBL739211

SCHEMBL739211

O=c1cc(-c2ccc(O)cc2)oc2cc3c(c(O)c12)OCO3

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.61
GABRP O00591 4/20 0.61
GABRD O14764 4/20 0.61
GABRA1 P14867 4/20 0.61
GABRB1 P18505 4/20 0.61
GABRG2 P18507 4/20 0.61
GABRB3 P28472 4/20 0.61
GABRA5 P31644 4/20 0.61
GABRA3 P34903 4/20 0.61
GABRA2 P47869 4/20 0.61
GABRB2 P47870 4/20 0.61
GABRA4 P48169 4/20 0.61
GABRE P78334 4/20 0.61
GABRA6 Q16445 4/20 0.61
GABRG1 Q8N1C3 4/20 0.61
GABRG3 Q99928 4/20 0.61
GABRQ Q9UN88 4/20 0.61
UGT1A1 P22309 3/20 0.61
PKM P14618 3/20 0.61
CYP1A1 P04798 3/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL971282 0.90 ABCB1 (0.61) KMT2AGABRPGABRDGABRA1GABRB1
SCHEMBL737402 0.87 MAPT (0.63) KMT2AGABRPGABRDGABRA1GABRB1
SCHEMBL6412437 0.80 UGT1A1 (0.65) KMT2AUGT1A1CYP1A1CYP1B1FTO
SCHEMBL737399 0.78 ACHE (0.53) ABCB1MAOAMAOBBCHEACHE
Pisonin E SCHEMBL30879929 0.77 PTGS1 (0.56) UGT1A1UGT1A8MAPTKDM4ECYP3A4
Scutellarein SCHEMBL29692708 0.76 KMT2A (1.00) KMT2AGABRPGABRDGABRA1GABRB1
Scutellarein SCHEMBL142093 0.76 KMT2A (1.00) KMT2AGABRPGABRDGABRA1GABRB1
Scutellarein SCHEMBL29004586 0.76 KMT2A (1.00) KMT2AGABRPGABRDGABRA1GABRB1
SCHEMBL24088771 0.75 CBS (0.82) KMT2AGABRPGABRDGABRA1GABRB1
Scutellarein SCHEMBL15090395 0.75 KMT2A (0.97) KMT2AGABRPGABRDGABRA1GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138165-B2 Chromones and chromone derivatives and uses thereof JENKEN BIOSCIENCES, INC. (US) 2012-03-20 US disclosed
EP-1556031-A4 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF JENKEN BIOSCIENCES INC (US) 2009-03-25 EP disclosed
US-20060142211-A1 Chromones and chromone derivatives and uses thereof TAIWANJ PHARMACEUTICALS CO., LTD. (TW) 2006-06-29 US disclosed
EP-1556031-A2 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF Jenken Bioscience, Inc. (US) 2005-07-27 EP disclosed
WO-2004037193-A2 CHROMONES AND CHROMONE DERIVATIVES AND USES THEREOF JENKEN BIOSCIENCES, INC. (US) 2004-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142211-A1 Chromones and chromone derivatives and uses thereof PROC, HMGB1, PYCARD KMT2A 4070/4885GABRP 4406/4885GABRD 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.